ALLIANCE A011502

Primary Category:

Cancer Control and Prevention Protocols, Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Open

A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

Patients previously enrolled in A011502 patients are eligible for enrollment in companion study A211601 and may be consented with A211601 Retrospective Consent.

Patients enrolling in A011502 patients must be enrolled in companion study A211601  and may be consented with A211601 Consent.

Eligible for screening study DCP 001

NCT#02927249

ALLIANCE A211601

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Open

Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502

NCT#03609021

Patients previously enrolled in A011502 are eligible to be enrolled in this protocol using the A211601 Retrospective Consent. 

Eligible for screening study DCP 001

Reconsents

The following protocols have consent changes requiring you to reconsent active patients (unless otherwise noted below).

MCC policy requires all reconsents be completed at the patient’s next scheduled office visit or within two weeks of MCC release of approved consent document, whichever is sooner.

(Please click the links for the available highlighted reconsents & letters.)

September 15th, 2020

September 1st, 2020

  • No consent changes requiring reconsents.

August 19th, 2020

August 18th, 2020

August 4th, 2020

July 21st, 2020

  • No consent changes requiring reconsents.

July 7th, 2020

June 16th, 2020

  • EA5163 – ALL Patients
  • S1609–  Active Patients ONLY

June 2nd, 2020

May 19th, 2020

May 7th, 2020

  • No consent changes requiring reconsents.

May 5th, 2020

  • No consent changes requiring reconsents.

April 23rd, 2020

  • No consent changes requiring reconsents.

April 21st, 2020

April 7th, 2020

March 17th, 2020

  • DT001ALL Patients
  • GU005ALL Patients
  • S1815Active Arm 1 pts ONLY

March 3rd, 2020

February 26th, 2020 – CIRB

February 2020 – Local IRB

  • No consent changes requiring reconsents.

February 14th, 2020 – CIRB

  • No consent changes requiring reconsents.

January 29th, 2020 – CIRB

  • No consent changes requiring reconsents.

January 2020 – Local IRB

  • No consent changes  requiring reconsents.

January 15th, 2020 – CIRB

January 2nd, 2020 – CIRB

December 2019 – Local IRB

December 16th, 2019 – CIRB

December 2nd, 2019 – CIRB

November 2019 – Local IRB

  • No consent changes requiring reconsents.

November 15th, 2019 – CIRB

November 1st, 2019 – CIRB

October 2019 – Local IRB

  • No consent changes requiring reconsents.

October 11th, 2019 – CIRB

October 4th, 2019 – CIRB

October 1st, 2019 – CIRB

September 2019 – Local IRB

  • No consent changes requiring reconsents.

September 16th, 2019 – CIRB

September 3rd, 2019 – CIRB

August 2019 – Local IRB

  • No consent changes requiring reconsents.

August 15th, 2019 – CIRB

August 1st, 2019 – CIRB

July 23rd, 2019 – CIRB

July 2019 – Local IRB

July 15th, 2019 – CIRB

July 1st, 2019 – CIRB

June 2019 – Local IRB

June 14th, 2019 – CIRB

May 31st, 2019 – CIRB

May 15th, 2019 – CIRB

May 1st, 2019 – CIRB

  • No consent changes requiring reconsents.

April 26th, 2019 – CIRB

April 15th, 2019 – CIRB

April 2019 – Local IRB

  • No consent changes requiring reconsents.

April 1st, 2019 – CIRB

  • E1910 – Pts receiving Blinatumomab ONLY

March 15th, 2019 – CIRB

March 2019 – Local IRB

  • No consent changes requiring reconsents.

March 1st, 2019 – CIRB

February 2019 – Local IRB

  • No consent changes requiring reconsents.

February 15th, 2019 – CIRB

February 1st, 2019 – CIRB

January 2019 – Local IRB

  • No consent changes requiring reconsents.

January 15th, 2019 – CIRB

January 2nd, 2019 – CIRB

[/members_only]